Microbiome Partnering Worldwide, 2010 to 2022 - Dealmaking Trends by the World's Leading Healthcare Companies in the Biopharma Industry Since 2010

News provided by

Aug 19, 2022, 09:15 ET

DUBLIN, Aug. 19, 2022 /PRNewswire/ -- The "Global Microbiome Partnering Terms and Agreements 2010 to 2022" report has been added to ResearchAndMarkets.com's offering.

The Global Microbiome Partnering Terms and Agreements 2010 to 2022 report provides an understanding and access to the Microbiome partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in Microbiome dealmaking in the biopharma industry since 2010
Access to headline, upfront, milestone and royalty data
Access to over 250 Microbiome deal records and contract documents where available
The leading antibody deals by value since 2010
Most active Microbiome dealmakers since 2010
The leading Microbiome partnering resources

The Global Microbiome Partnering Terms and Agreements report provides an understanding and access to the Microbiome partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Microbiome partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Microbiome technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual Microbiome deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What are the precise rights granted or optioned?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of Microbiome dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Microbiome dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Microbiome deals since 2010. Deals are listed by headline value, signed by big pharma, most active Microbiome dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Microbiome dealmaking with a brief summary followed by a comprehensive listing of Microbiome deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Microbiome partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Microbiome partnering deals signed and announced since Jan 2010. The chapter is organized by specific Microbiome technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Microbiome partnering company A-Z, deal type definitions and Microbiome partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Microbiome partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Microbiome technologies and products.

Companies Mentioned

4D Pharma
9 Meters Biopharma
Aarhus University
Abbott Laboratories
Abbvie
ADL Bionatur Solutions
ADM
AIDS Clinical Trials Group
Alimentary Health
Allergan
ALS Association
Amag Pharmaceuticals
American Type Culture Collection (ATCC)
Ancilia Biosciences
AnimalBiome
AntibioTx
Arc Bio
Archer Daniels Midland Company
Arena Pharmaceuticals
Argonne National Laboratory
Ariana Pharma
Arranta Bio
Artizan Biosciences
Assembly Biosciences
AstraZeneca
Aurealis Therapeutics
Azitra
BASF
Bayer
Bayer CropScience
Bayer Healthcare
Baylor College of Medicine
Baylor Miraca Genetics Laboratories
Beam Therapeutics
Bertin Pharma
Bill and Melinda Gates Foundation
Bio-Me
Bio-Rad Laboratories
BIOASTER
Biocodex Microbiota Foundation
Biocogent
Biocore
Biofortis
Biohaven Pharmaceuticals
BiomeBank
Biomecite Diagnostics
Biomedical Advanced Research and Development Authority
Biomica
Biomillenia
Biomodels
BiomX
BionX Medical Technologies
Bio Palette
Biosortia Pharmaceuticals
Bloom Science
Boehringer Ingelheim
Boston University School of Medicine
Brigham and Women's Hospital
Bristol-Myers Squibb
Brown University
Cancer Research UK
CARB-X
Carbiotix
Cargill
Cedars-Sinai Medical Center
Centers for Disease Control and Prevention
Centre Leon Berard
Centre National de la Recherche Scientifique
Centro Sperimentale del Latte
Children's Hospital Boston
Circuit Clinical
Clalit Health Services
and many, many more!

For more information about this report visit https://www.researchandmarkets.com/r/gxcyja

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets